The 5-year partnership will begin with integration, enabling global go-to-market deployments, but will also combine Atos's expertise in driving digital adoption, support, and infrastructure with Huma's digital care, clinical trials, and biomarkers.
FREMONT, CA: Atos and Huma, the digital health innovator, have announced a 5-year strategic global partnership to shift healthcare and clinical trials from hospital to home. The partnership will focus on Huma's modular platform, which can power digital 'hospitals at home' up to national scale and support pharmaceutical and research industries to run complex global decentralized clinical trials. The platform is already used in the US and across Europe for illnesses ranging from atrial fibrillation to diabetes to Covid-19.
Atos will use its experience in implementing and scaling complex transformation projects to accelerate the adoption of Huma's technology. This will include investment by Atos worth up to €20 million split across R&D and go-to-market resources, including dedicated consulting and sales personnel. The investment in R&D will fast-track the integration of the Huma platform with other leading clinical platforms and develop a dedicated video module.
Atos and Huma's approach means patients are monitored outside of the hospital and given timely, proactive clinical intervention ahead of need, ultimately optimizing the use of resources, improving patient outcomes, and reducing long-term healthcare costs. Early-stage evidence has shown Huma's service, which has already been operating nationally across Germany, England, and the UAE can almost double hospital capacity.
